Cardiff Oncology, Inc.
CRDF
$1.05
-$0.05-4.55%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 33.79% | 8.11% | 38.78% | 5.04% | -18.38% |
| Total Depreciation and Amortization | -3.06% | -3.07% | -3.46% | -5.08% | -4.58% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -38.06% | 27.61% | 5.45% | 3.28% | 31.37% |
| Change in Net Operating Assets | -190.18% | -112.13% | -131.69% | -1,491.04% | 218.79% |
| Cash from Operations | -41.27% | 3.95% | 41.88% | -3.62% | 9.77% |
| Capital Expenditure | -69.23% | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 348.40% | 122.33% | 138.28% | 207.89% | -135.37% |
| Cash from Investing | 346.22% | 122.33% | 138.28% | 207.70% | -135.55% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 3,400.00% | -94.22% | -99.66% | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 3,400.00% | -94.22% | -99.66% | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 104.91% | 67.39% | -80.91% | 94.79% | -294.52% |